SCYNEXIS, Inc.

SCYX ·Healthcare, Drug Manufacturers - General, United States

Business Overview: SCYNEXIS, Inc. (Nasdaq: SCYX)

Executive Summary

SCYNEXIS, Inc. is a commercial-stage biotechnology company based in Jersey City, New Jersey, focused on the discovery, development, and commercialization of novel antifungal therapies for hard-to-treat and often drug-resistant fungal infections. The company's proprietary chemistry platform produced ibrexafungerp, the first approved representative of a new antifungal class the company calls "fungerps" (triterpenoid antifungals), marketed in the U.S. as BREXAFEMME.

SCYNEXIS matters less for its current revenue scale than for what it represents in a therapeutic area that has seen almost no genuine innovation in decades: a mechanistically differentiated antifungal that doesn't share cross-resistance with the azole drugs (like fluconazole) that dominate the market. In 2023 the company licensed ibrexafungerp's global commercialization rights to GSK, converting itself from a direct commercial-stage company into a royalty-and-milestone-driven biotech funding a next-generation pipeline candidate, SCY-247.

1. Core Business Model & How They Work

SCYNEXIS no longer sells BREXAFEMME directly to patients and providers — since the 2023 GSK deal, its economics run through licensing, milestones, and royalties rather than direct product sales.

[ Fungerp Drug Discovery Platform ] ➡️ [ Clinical Development (Ph1-3) ] ➡️ [ FDA Approval ] ➡️ [ Out-License to GSK (global rights) ] ➡️ [ Milestones + Royalties on Net Sales ]

Key Operational Drivers

Out-licensed commercial asset: BREXAFEMME (ibrexafungerp) is FDA-approved for vulvovaginal candidiasis (VVC) and reduction in recurrent VVC. SCYNEXIS transferred the U.S. NDA for BREXAFEMME to GSK in November 2025; GSK now controls regulatory strategy, manufacturing, and commercialization globally under an exclusive, royalty-bearing, sublicensable license signed March 30, 2023 (amended by MOUs in December 2023 and October 2025).
Milestone-driven revenue: SCYNEXIS recognizes development and regulatory milestones from GSK as they are achieved. In the three months ended June 30, 2025, it billed GSK a $10.0 million development milestone after the FDA lifted a clinical hold on ibrexafungerp. Under the October 2025 binding MOU that wound down the Phase 3 MARIO study (oral ibrexafungerp as step-down therapy for invasive candidiasis after IV echinocandin treatment), GSK made one-time, non-refundable payments totaling $24.8 million.
Pipeline reinvestment: Proceeds fund SCY-247, a next-generation fungerp currently in Phase 1, with a Phase 2 study in invasive candidiasis planned for 2026 — the company's next attempt at a wholly-owned commercial asset.
Capital discipline: As of December 31, 2025, SCYNEXIS held cash, equivalents, and investments of $56.3 million against an accumulated deficit of roughly $385.1 million, reflecting the company's long and expensive road from discovery to its first approval.

2. Product Portfolio

Asset	Class / Stage	Purpose	Why It Matters
BREXAFEMME (ibrexafungerp)	First-in-class fungerp (triterpenoid); FDA-approved	Treats vulvovaginal candidiasis (VVC) and reduces recurrence of VVC (rVVC)	The only approved oral antifungal with a non-azole mechanism in this indication; now licensed to GSK globally, with GSK expected to begin FDA discussions in 2026 about relaunching it commercially in the U.S.
Ibrexafungerp (IV/oral, broader use)	Same molecule, invasive fungal infection development	Step-down oral therapy after IV echinocandin treatment for invasive candidiasis/candidemia	The core rationale for the terminated MARIO Phase 3 study; GSK retains global rights but will not fund further MARIO-specific milestones after the October 2025 wind-down.
SCY-247	Second-generation fungerp; Phase 1	Targets a broader range of invasive fungal infections with improved properties over ibrexafungerp	SCYNEXIS's own next wholly-owned commercial opportunity and the main justification for continued R&D spend; Phase 2 in invasive candidiasis planned for 2026.

3. Competitive Landscape

Antifungal drugs are typically grouped by mechanistic class, and SCYNEXIS's 10-K names competitors across all of them:

Azoles (the dominant, mostly generic incumbents): Diflucan (fluconazole, Pfizer), Noxafil (posaconazole, Merck), Cresemba (isavuconazole, Astellas), Vivjoa (oteseconazole, Mycovia) — Vivjoa is the most direct branded competitor in recurrent VVC. Terazol (Janssen) and Gynazole (Perrigo) compete in acute VVC.
Echinocandins (IV-only, used for invasive infections): Rezzayo (rezafungin, Melinta), plus generic Cancidas (caspofungin), Mycamine (micafungin), and Eraxis (anidulafungin, Pfizer).
Polyenes: AmBisome (liposomal amphotericin B; Gilead/Astellas/Dainippon-Sumitomo), used as a broad-spectrum fallback.
Pipeline competitors: Fosmanogepix (Basilea), MAT2203 (Matinas), and Olorofim (F2G) — each targeting similar unmet need in resistant or invasive fungal disease.

ANTIFUNGAL POSITIONING
┌───────────────────────────────────────────────────────┐
│ High  │                                                │
│   N   │          [SCY-247 target] [Fosmanogepix]       │
│   O   │                                                │
│   V   │   [Rezzayo]        [Ibrexafungerp/BREXAFEMME]  │
│   E   │                                                │
│   L   │                                                │
│   T   │  [Generic echinocandins]                       │
│   Y   │                                                │
│       │ [Diflucan/generic azoles]  [AmBisome]           │
│  Low  │                                                │
│       └────────────────────────────────────────────►  │
│         Low      RESISTANCE-FREE MECHANISM      High   │
└───────────────────────────────────────────────────────┘

SCYNEXIS's durable differentiator is mechanism, not price: fungerps avoid cross-resistance with the azole class that dominates the market but is increasingly undermined by rising fluconazole-resistant Candida strains.

4. Strategic Strengths & Risks

Strengths

First-in-class mechanism: Ibrexafungerp was the first new oral antifungal class approved by the FDA in over 20 years, giving SCYNEXIS genuine scientific intangible-asset value even after out-licensing commercial rights.
De-risked economics via GSK: The 2023 license shifted commercialization cost and risk to a large pharma partner, while preserving royalty and milestone upside, letting SCYNEXIS focus cash on earlier-stage pipeline work.
Narrowing losses, growing revenue: Net loss fell to $8.6 million in 2025 from $21.3 million in 2024, as total revenue rose to $20.6 million from $3.7 million, largely on GSK milestone and MARIO wind-down payments.

Risks

Partner dependency: Nearly all near-term revenue now depends on GSK's decisions — including whether and when GSK relaunches BREXAFEMME commercially in the U.S. (discussions are not expected to begin with the FDA until 2026) and whether further milestones are ever triggered.
MARIO termination overhang: SCYNEXIS disputed GSK's right to unilaterally terminate the Phase 3 MARIO study before the parties settled on a wind-down and the $24.8 million payment — a reminder that SCYNEXIS no longer controls the clinical and commercial fate of its lead asset.
High cash burn history and reliance on binary pipeline bets: With a $385.1 million accumulated deficit against $56.3 million of cash and investments, continued funding of SCY-247 depends on either milestone receipts or future capital raises.
Commoditized competitive base: Most VVC prescriptions still go to cheap generic fluconazole; BREXAFEMME/ibrexafungerp must win share from a well-entrenched, low-cost standard of care.

5. Financial Overview

Metric	FY2025	FY2024	Strategic Context
Total Revenue	$20.6M	$3.7M	Growth driven by GSK milestone ($10.0M) and MARIO wind-down payment ($24.8M across the MOU), not organic product sales.
Net Loss	$(8.6M)	$(21.3M)	Loss narrowed sharply as license/milestone revenue offset R&D and SG&A spend.
Cash, Equivalents & Investments	$56.3M	n/a	Primary runway for SCY-247 development; no debt reliance disclosed.
Accumulated Deficit	~$385.1M	n/a	Reflects two decades of drug development investment prior to first approval and monetization.
Exchange / Listing	Nasdaq Capital Market (SCYX)	—	Small-cap biotech; valuation highly sensitive to GSK partnership news and SCY-247 trial readouts.

6. Summary Conclusion

SCYNEXIS has converted a hard-won scientific breakthrough — the first new oral antifungal mechanism in a generation — into a capital-light royalty and milestone business by handing commercialization of BREXAFEMME to GSK, while using the proceeds to fund a next-generation candidate, SCY-247. The model meaningfully reduces commercial execution risk relative to a typical small biotech trying to sell its own drug, but it also concentrates nearly all near-term financial outcomes in decisions GSK makes about relaunch timing, further trial investment, and milestone triggers — as the contentious MARIO study termination in 2025 illustrated. The company's future now rests on whether SCY-247 can become SCYNEXIS's own, wholly-owned commercial success before its cash runway runs out.